Novo Nordisk presented data from STEP UP at the European Congress on Obesity Day 1 today, and two findings from the program reframe how the higher-dose injectable semaglutide is positioned. First: a defined “early responder” subgroup on the 7.2 mg dose achieved 27.7% weight loss at Week 72 — approaching the territory of Lilly’s retatrutide (28.7% in TRIUMPH-4) with an already-approved, already-launched drug. Second: an MRI sub-study confirms that 84% of total weight loss is fat mass — directly answering the most persistent criticism of GLP-1 therapy.

The two findings together change the editorial story about Wegovy HD. Novo’s higher-dose injectable was approved in April as an extension of the existing Wegovy product line, with the implicit positioning of being for patients plateaued on 2.4 mg. The STEP UP data positions Wegovy 7.2 mg differently: as efficacy-competitive with the next-generation triple agonists at the upper end of the response curve.

The Early Responder Finding

Novo defined an “early responder” as a patient achieving ≥15% weight loss by Week 24 — approximately six months of treatment. The proportions qualifying:

• Semaglutide 7.2 mg: 27% of patients (roughly 1 in 4)
• Semaglutide 2.4 mg: 21% of patients
• Placebo: 3% of patients

For the 7.2 mg early-responder cohort, Week 72 outcomes were striking: a mean of −27.7% weight loss. That’s approximately 65 pounds for a baseline-100-kg patient, which approaches the 28.7% / ~71 pound figure that retatrutide’s 12 mg dose produced in the TRIUMPH-4 trial.

The strategic implication: 27% of patients on the highest-dose injectable semaglutide can achieve weight loss in the same range as the next-generation triple agonist Lilly is developing. The drug is approved, launched, available, and reimbursed in ways retatrutide may not be for another 18–24 months. The patient population that responds to GLP-1 monotherapy at high doses does not need to wait for retatrutide approval to access comparable efficacy.

The clinical-utility framing also matters. Early response identification at Week 24 lets clinicians and patients make dose-escalation, continuation, or alternative-therapy decisions efficiently. Patients who are early responders by Week 24 are likely to continue achieving substantial weight loss through Week 72; patients who are not early responders may need different therapeutic approaches.

The MRI Sub-Study

The most cited concern about GLP-1 weight loss has been muscle loss — the fear that the rapid weight reduction these drugs produce comes substantially at the expense of lean mass rather than fat mass. Novo’s MRI sub-study in STEP UP directly addresses this with imaging evidence.

The sub-study enrolled 55 participants from the broader STEP UP population. Magnetic resonance imaging measured body composition at baseline and at the trial’s endpoint.

Headline results:

• Fat mass contribution to total weight loss: 84%. The vast majority of weight loss on semaglutide is fat mass reduction. The remaining 16% is lean mass — within the range expected for any significant weight reduction, including weight loss from diet and exercise alone.
• Visceral fat reduction: >30%. Reduction in abdominal visceral fat — the metabolically active fat associated with cardiovascular and metabolic disease risk — exceeded 30%.
• Muscle function preserved. A 30-second sit-to-stand test, a standard clinical measure of functional muscle strength, showed equivalent improvements in the semaglutide and placebo arms. No impairment of muscle function despite substantial total weight loss.
• Muscle quality improved. Intramuscular fat content (fatty infiltration of muscle tissue, an indicator of poor muscle quality) decreased — meaning the muscle that remained was qualitatively better.

The MRI sub-study is the strongest body-composition evidence the GLP-1 class has produced to date. The findings directly contradict the “GLP-1s cause muscle loss” narrative that has dominated social media and skeptical media coverage of the class for two years.

What’s Different About Wegovy 7.2 mg

Wegovy HD (the higher-dose 7.2 mg formulation) became available in the United States in April 2026, with introductory pricing through June 30, 2026 ($199 monthly during titration). The dose was approved as an extension of the existing Wegovy injectable product line.

Three things to understand about the higher dose:

The 7.2 mg dose is achieved through titration. Patients do not start at 7.2 mg. They titrate up from lower doses over months, allowing GI tolerability adaptation. The STEP UP early-responder data is consistent with this: the patients who tolerate titration and reach the 7.2 mg dose are the population most likely to be early responders.

The efficacy gap between 2.4 mg and 7.2 mg is meaningful but not dispositive. The mean weight loss across all 7.2 mg patients (not just early responders) was approximately 20.7% at Week 72, versus approximately 18.2% at Week 72 for 2.4 mg. The gap is real but the 2.4 mg dose remains highly efficacious for the broader patient population.

The body composition findings apply across the dose range. The 84% fat / 16% lean mass split was observed in the STEP UP MRI sub-study at the 7.2 mg dose; the underlying mechanism — appetite-mediated weight loss with adequate protein intake — is consistent across doses.

What This Means

For patients on Wegovy 2.4 mg considering whether to escalate to 7.2 mg: the early-responder data provides a clinically meaningful framework. Patients who achieve ≥15% weight loss by Week 24 on 7.2 mg are likely to continue toward the 27%+ trajectory; the dose escalation pays off for these patients. Patients who are not early responders may face a different cost-benefit calculation.

For the broader GLP-1 competitive landscape: Wegovy 7.2 mg sets a meaningful efficacy benchmark that competes with the next-generation triple agonists at the upper end of the response curve. Retatrutide will still produce higher mean weight loss across the broader treatment population (because the early-responder cohort is roughly a quarter of all 7.2 mg patients, while retatrutide’s 12 mg produces 28%+ across a broader response curve), but the head-to-head efficacy gap in the most-responsive patient population is smaller than the headline comparisons suggest.

For the muscle-loss narrative: the MRI sub-study is now the citation that addresses the criticism. The data does not eliminate concern entirely — every weight reduction includes some lean mass loss — but it does demolish the framing that GLP-1 weight loss is disproportionately muscle.

References

1. Higher Dose Wegovy Demonstrates Nearly 28% Weight Loss in Early Responders According to New Analyses Presented at the European Congress on Obesity. Novo Nordisk. May 12, 2026. GlobeNewsWire
2. Novo Nordisk: Higher Dose Wegovy 28% Early Responders. BioSpace. May 12, 2026. BioSpace
3. Novo Nordisk ECO Data. Manila Times. May 12, 2026. Manila Times